FindTrial
Sign In

Systematic review and meta-analysis for the 2026 update of the Japanese clinical practice guidelines for the management of membranous nephropathy

Systematic review and meta-analysis for the 2026 update of the Japanese clinical practice guidelines for the management of membranous nephropathy - Membranous nephropathy CPG update 2026

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000055113
Enrollment
Unknown
Registered
2024-08-01
Start date
2024-03-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic membranous nephrooathy

Interventions

None listed

Sponsors

Showa University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: randomized control trials

Exclusion criteria

Exclusion criteria: Secondary membranous nephropathy

Design outcomes

Primary

MeasureTime frame
Total death Renal death (dialysis induction or renal transplantation) Development of infection Recurrence of nephrosis Nephrotic remission (complete or incomplete) Decline in renal function (sCr or CCr or GFR) Quality of Life Length of hospital stay, number of hospitalizations—

Countries

Japan

Contacts

Public ContactHiroki Nishiwaki

Showa University Fujigaoka Hospital Division of Nephrology, Department of Internal Medicine

nwacky1978@med.showa-u.ac.jp+81-45-971-1151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026